Ufa Eye Research Institute, Ufa, Bashkortostan, Russia.
Experimentica Ltd, Kuopio, Finland.
Int Ophthalmol. 2021 Jun;41(6):2053-2063. doi: 10.1007/s10792-021-01761-w. Epub 2021 Mar 13.
To examine the compatibility of intravitreally injected epidermal growth factor (EGF) and amphiregulin as EGF family member.
Four rabbits (age: 4 months; body weight: 2.5 kg) received three intravitreal injections of EGF (100 ng) uniocularly in monthly intervals and underwent ocular photography, tonometry, biometry, and optical coherence tomography. After sacrificing the rabbits, the globes were histomorphometrically examined. In a second study part, eyes of 22 guinea pigs (age: 2-3 weeks) received two intravitreal administrations of amphiregulin (10 ng) or phosphate buffered solution (PBS) in 10-day interval, or were left untouched. Ten days after the second injection, the guinea pigs were sacrificed, the enucleated eyes underwent histological and immune-histological examinations.
The rabbit eyes with EGF injections versus the contralateral untouched eyes did not show significant differences in intraocular pressure (7.5 ± 2.4 mmHg vs. 6.8 ± 2.2 mmHg; P = 0.66), retinal thickness (158 ± 5 µm vs. 158 ± 3 µm; P = 1.0), cell counts in the retinal ganglion cell layer (3.3 ± 1.7 cells/150 µm vs. 3.0 ± 1.4 cells/150 µm; P = 0.83), inner nuclear layer (46.4 ± 23.2 cells/150 µm vs. 39.6 ± 6.4 cells/150 µm; P = 0.61), and outer nuclear layer (215 ± 108 cells/150 µm vs. 202 ± 47 cells/150 µm; P = 0.83), or any apoptotic retinal cells. The guinea pig eyes injected with amphiregulin versus eyes with PBS injections did not differ (P = 0.72) in the degree of microglial activation, and both groups did not differ from untouched eyes in number of apoptotic retinal cells and retinal gliosis.
Intravitreal applications of EGF (100 ng) in rabbits nor intravitreal applications of amphiregulin (10 ng) in guinea pigs led to intraocular specific inflammation or any observed intraocular destructive effect. The findings support the notion of a compatibility of intraocular applied EGF and amphiregulin.
研究目的在于考察玻璃体内注射表皮生长因子(EGF)和双调蛋白作为 EGF 家族成员的兼容性。
4 只兔子(年龄:4 个月;体重:2.5kg)每月单侧玻璃体内注射 EGF(100ng),共 3 次,并进行眼部摄影、眼压测量、生物测量和光学相干断层扫描。处死兔子后,对眼球进行组织形态计量学检查。在第二部分研究中,22 只豚鼠(年龄:2-3 周)的双眼在 10 天的间隔内接受两次玻璃体内注射双调蛋白(10ng)或磷酸盐缓冲液(PBS),或不进行处理。第二次注射后 10 天,处死豚鼠,眼球经眼球摘除后进行组织学和免疫组织化学检查。
与对侧未处理眼相比,接受 EGF 注射的兔子眼的眼内压(7.5±2.4mmHg 与 6.8±2.2mmHg;P=0.66)、视网膜厚度(158±5μm 与 158±3μm;P=1.0)、视网膜神经节细胞层的细胞计数(3.3±1.7 个/150μm 与 3.0±1.4 个/150μm;P=0.83)、内核层(46.4±23.2 个/150μm 与 39.6±6.4 个/150μm;P=0.61)和外核层(215±108 个/150μm 与 202±47 个/150μm;P=0.83)或任何凋亡的视网膜细胞均无显著差异。与 PBS 注射组相比,接受双调蛋白注射的豚鼠眼的小胶质细胞激活程度无差异(P=0.72),两组的凋亡视网膜细胞数量和视网膜胶质增生与未处理眼均无差异。
在兔子中玻璃体内应用 EGF(100ng)或在豚鼠中玻璃体内应用双调蛋白(10ng)均未导致眼内特异性炎症或任何观察到的眼内破坏性效应。这些发现支持眼内应用 EGF 和双调蛋白具有兼容性的观点。